A Phase 1, Open-label, Single Center Study of KYV-101, an Autologous Fully-human Anti-CD19 Chimeric Antigen Receptor T-Cell (CD19 CAR T) Therapy, in Subjects with Non-relapsing and Progressive Forms of Multiple Sclerosis (S3.001)
Year: 2025
Type: article
Study design: Clinical Trial
Source: Neurology
Authors: Jeffrey Dunn, Kristin Galetta, Anna Tomczak, Garrett Timmons, Crystal Ton-Nu, Julia Sumera, Emma Martinez, Robert Lowsky
Institution: Stanford University
Language: English
Subfield: Pathology and Forensic Medicine
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4409227527